Neoadjuvant Therapy
FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer
Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy
FDA Approves AstraZeneca’s Imfinzi for Use Before and After Lung Cancer Surgery
FDA approval, AstraZeneca, Imfinzi, lung cancer, surgery, neoadjuvant, adjuvant, durvalumab, NSCLC